Bulumtatug Fuvedotin(BFv,9MW2821),一种新一代靶向Nectin-4的抗体药物偶联物,用于晚期实体瘤患者:一项首次人体、开放标签、多中心、I/II期研究
这项首次人体、开放标签、多中心I/II期研究评估了靶向Nectin-4的抗体药物偶联物BFv在既往系统治疗失败的晚期实体瘤患者中的安全性和初步抗肿瘤活性。2022年6月11日至2024年4月3日共入组274例患者,推荐的II期剂量为1.25 mg/kg。在1.25 mg/kg组221例可评估疗效患者中,尿路上皮癌、宫颈癌、食管癌和三阴性乳腺癌的客观缓解率分别为54.1%、32.1%、14.0%和50%。
要点
- BFv推荐的II期剂量为1.25 mg/kg,基于安全性与疗效的平衡确定。
- 1.25 mg/kg组最常见≥3级治疗相关不良事件包括中性粒细胞计数降低、白细胞计数降低、贫血、γ-谷氨酰转移酶升高伴皮疹及外周感觉神经病变。
- 1.25 mg/kg组客观缓解率:尿路上皮癌54.1%、宫颈癌32.1%、食管癌14.0%、三阴性乳腺癌50%。
核心结论
- 结果提示BFv在除尿路上皮癌外的多种实体瘤中耐受性可接受且疗效具有临床意义。
- 多项关键性试验正在进行中(NCT06196736、NCT06592326、NCT06692166)。
研究设计与样本
- 首次人体、开放标签、多中心研究,包括剂量递增、剂量扩展和队列扩展阶段。
- 入组既往一线或多线系统治疗失败的晚期实体瘤患者,接受BFv静脉输注,剂量0.33-1.5 mg/kg,每28天周期第1、8、15天给药。
- 主要目标为评估安全性和初步疗效(NCT05216965,CTR20220106)。
- 2022年6月11日至2024年4月3日共入组274例患者,包括尿路上皮癌51例、宫颈癌62例、食管癌49例、三阴性乳腺癌20例及其他实体瘤92例。
主要发现
- 剂量递增阶段,1.5 mg/kg组观察到1例剂量限制性毒性,为持续>5天的4级中性粒细胞减少。
- BFv的最大耐受剂量未达到;基于安全性与疗效的平衡,推荐的II期剂量确定为1.25 mg/kg。
- 1.25 mg/kg组最常见的≥3级治疗相关不良事件为中性粒细胞计数降低、白细胞计数降低、贫血、γ-谷氨酰转移酶升高伴皮疹及外周感觉神经病变。
- 1.25 mg/kg组221例可评估疗效患者中,客观缓解率在尿路上皮癌为54.1%、宫颈癌为32.1%、食管癌为14.0%、三阴性乳腺癌为50%。
关键数值与推荐
- 推荐的II期剂量为1.25 mg/kg。
- 1.25 mg/kg组客观缓解率:尿路上皮癌54.1%、宫颈癌32.1%、食管癌14.0%、三阴性乳腺癌50%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A first-in-human study was carried out to assess the safety and preliminary antitumor activity of bulumtatug fuvedotin (BFv; 9MW2821), a next-generation monoclonal antibody-drug conjugate (ADC) that delivers monomethylauristatin E (MMAE) to cells expressing Nectin-4, in patients with advanced solid tumors. PATIENTS AND METHODS: This was a first-in-human, open-label, multicenter study and included dose escalation, dose expansion and cohort expansion periods. Patients with advanced solid tumors who failed one or more lines of systemic therapy were recruited to receive BFv by intravenous (IV) infusion at doses of 0.33-1.5 mg/kg on days 1, 8 and 15 of each 28-day cycle. Primary objective was assessment of safety and preliminary efficacy. (NCT05216965, CTR20220106). RESULTS: Between 11 June 2022 and 3 Apr 2024, 274 patients were enrolled, including 51 with urothelial cancer, 62 with cervical cancer, 49 with esophageal cancer, 20 with triple-negative breast cancer and 92 with other solid tumors. In the dose escalation phase, one dose-limiting toxicity was observed in the 1.5 mg/kg group, which was grade 4 neutropenia that lasted >5 days. Maximum tolerated dose of BFv was not reached. However, the recommended phase II dose was identified as 1.25 mg/kg based on a balance of safety and efficacy. The most common grade ≥3 treatment-related adverse events were decreased neutrophil count, decreased white blood cell count, anemia, increased gamma-glutamyl transferase (GGT) with rash, and peripheral sensory neuropathy in the 1.25 mg/kg group. Among 221 patients assessable for efficacy in 1.25 mg/kg group, objective response rates were 54.1%, 32.1%, 14.0% and 50% in urothelial cancer, cervical cancer, esophageal cancer and triple-negative breast cancer, respectively. CONCLUSIONS: The results suggest that BFv was tolerable and clinically significant in efficacy in various types of solid tumors besides urothelial cancer. Several pivotal trials are currently in progress (NCT06196736, NCT06592326, NCT06692166).
引用
- Zhang J, Liu R, Wang S, et al. Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation Nectin-4 targeting antibody-drug conjugate, in patients with advanced solid tumors: a first-in-human, open-label, multicenter, phase I/II study. Ann Oncol. 2025. PMID: 40288679. doi:10.1016/j.annonc.2025.04.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。